Differential Diagnosis and Treatment of Low Hemoglobin

Initial Diagnostic Approach

The American Society of Clinical Oncology recommends that before initiating any treatment for low hemoglobin, the underlying cause should be systematically identified and corrected through targeted diagnostic evaluation, as treating anemia without addressing the etiology can mask serious conditions and delay appropriate therapy 1
A thorough drug exposure history should be documented, particularly for medications causing oxidative stress, such as benzocaine, prilocaine, lidocaine, dapsone, and sulfonamides, as recommended by the American Journal of Hematology 2, 3
Blood loss assessment should evaluate for occult gastrointestinal bleeding, menstrual history, and recent trauma, according to the Journal of Clinical Oncology 1
Chronic disease screening should assess for inflammatory conditions, autoimmune diseases, malignancy, and renal insufficiency, as suggested by the Journal of Clinical Oncology 1
Nutritional history should identify dietary deficiencies and malabsorption symptoms, as recommended by the Journal of Clinical Oncology 1

For iron deficiency anemia, the European Society for Medical Oncology recommends a target hemoglobin of 12 g/dL, with intravenous iron preferred for patients with ongoing chemotherapy or functional iron deficiency, and oral iron supplementation for mild cases without malabsorption 4
For anemia of chronic disease, the American Society of Clinical Oncology recommends addressing the underlying inflammatory condition first, and considering erythropoiesis-stimulating agents (ESAs) only in chemotherapy-associated anemia when hemoglobin is less than 10 g/dL and symptomatic 1, 4
For normocytic anemia due to acute blood loss, the American Journal of Hematology recommends immediate hemodynamic stabilization, red blood cell transfusion for hemodynamically unstable patients, and identification and control of the bleeding source 4, 5, 6
For anemia of chronic kidney disease, the National Kidney Foundation recommends correcting iron deficiency first, and considering ESAs if hemoglobin is less than 10 g/dL and symptomatic, while avoiding ESAs in patients not receiving chemotherapy 1, 4

For methemoglobinemia, the American Journal of Hematology recommends asymptomatic or minimally symptomatic observation with oxygen supplementation, and methylene blue treatment for symptomatic patients with methemoglobin levels greater than 20% (acquired) or 30% (hereditary) 2, 3, 5
For hemochromatosis with concurrent anemia, the European Association for the Study of the Liver recommends investigating other unrelated causes of anemia thoroughly, and considering mini-phlebotomies plus subcutaneous deferoxamine for patients unable to tolerate phlebotomy due to anemia 6, 7
For cancer-associated anemia, the American Society of Clinical Oncology recommends ESA therapy only for patients receiving chemotherapy, with hemoglobin less than 10 g/dL and symptoms, or less than 8 g/dL without symptoms, and correcting iron deficiency first 1, 4

The American Society of Clinical Oncology warns against initiating ESAs without correcting iron deficiency first, as it may worsen anemia and increase the risk of adverse events 1, 4
The American Journal of Hematology warns against using methylene blue in patients with G6PD deficiency, as it may cause severe hemolysis 2, 3
The European Association for the Study of the Liver warns against assuming anemia in hemochromatosis is related to iron overload, and recommends investigating other causes of anemia 6, 7
The American Society of Clinical Oncology warns against using ESAs in cancer patients not receiving chemotherapy, as it may increase the risk of mortality 4

The American Society of Clinical Oncology recommends red blood cell transfusion for hemodynamically unstable patients, severe symptomatic anemia with hemoglobin less than 7-8 g/dL, acute coronary syndrome or severe cardiopulmonary disease with hemoglobin less than 8-10 g/dL, and as an alternative to ESAs in chemotherapy-associated anemia 1, 4